Akari Therapeutics Announces Samir R. Patel, M.D., Has Assumed The Role Of Interim President & CEO, Increases Ownership To 14.2% With $1.25M Investment In Recent Private Placement

• Interim CEO employment contract consists solely of equity compensation
  
   
• Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m investment in recent private placement

BOSTON and LONDON, June 05, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), an innovative biotechnology company advancing therapies for autoimmune and inflammatory diseases, in follow up to the May 1st announcement that Samir R. Patel, M.D., has assumed the role of Interim President & CEO, provides detail of Dr. Patel's employment compensation. Dr Patel's employment contract reaffirms his desire to align his success directly with the success of the company's shareholders.